BLAINJECTIONINJECTABLEPriority Review
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
LEMTRADA (alemtuzumab) by Sanofi is cd52-directed antibody interactions [moa]. Approved for multiple sclerosis, relapsing-remitting, chronic lymphocytic leukemia. First approved in 2001.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEMTRADA (alemtuzumab) is a CD52-directed monoclonal antibody that depletes lymphocytes through cytolytic mechanisms. It treats multiple sclerosis, chronic lymphocytic leukemia, and multiple other hematologic and autoimmune conditions across transplantation and rare disease indications. The drug works by binding CD52 antigen on B and T cells, triggering antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
$0.909MPart D
LOE ApproachingProduct is approaching loss of exclusivity with minimal Medicare Part D utilization (12 claims in 2023), indicating small commercial footprint and likely contracting team support rather than growth initiatives.
Mechanism of Action
CD52-directed Antibody Interactions
Pharmacologic Class:
CD52-directed Cytolytic Antibody
Worked on LEMTRADA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.